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Targeting protein–protein interaction with small molecules is a challenging task because of drugga-
bility issues. Nevertheless, several studies on the kinetics as well as thermodynamic properties of
protein–protein interactions have immensely contributed toward better understanding of the affin-
ity of these complexes. But, more recent studies on hot spots and interface residues have opened up
new avenues in the drug discovery process. This approach has been used in the design of hot spot
based modulators targeting protein–protein interaction with the objective of normalizing such inter-
actions.
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Protein–protein interaction is an important driving mechanism
in many physiological processes in the cell and may also be
involved in the pathogenesis of some diseases such as Alzhei-
mer’s cervical cancer, bacterial infection and prion diseases
(Cohen and Prusiner, 1998; Selkoe, 1998; Loregian et al.,
2002). Owing to the diversity of protein–protein interactions
there is a need for careful investigation of the nature of the
protein interface. The protein interface residues are a determi-
nant of the specificity and stability of protein–protein interac-
tion. The size of the protein interface decides whether the
complex will be transient or obligatory. Protein–protein
interaction is regulated by environmental conditions such as
temperature, pH, ionic strength, etc. and also by cell
mechanisms such as enzymes, covalent modification and
non-covalent modification ligand binding etc (Furukawa
et al., 2002; Eyster, 1998; Klemm et al., 1998; Markus and
Benezra, 1999). Depending on their stability, protein com-
plexes can be principally classified into two types: temporary
and permanent stable complexes. The temporary complex
interfaces have unique properties for each interacting pair of
proteins whereas the permanent stable complex interfaces have
similar properties on their surfaces as their formation is con-
sidered to be a continuation of protein folding (Dmitriev
et al., 2002; Tsai et al., 1997).
Prediction of protein–protein interaction is crucial in drug
discovery. Many physiological and pathological cellular pro-
cesses depend on protein–protein interactions which can be
influenced by external compounds. The modern drug discovery
process involves three main steps-identification of prospective
drug target, investigating its properties and designing of a cor-
responding ligand (Archakov et al., 2003). Therefore, knowl-
edge of protein–protein interaction can be useful in designing
modulators that can target the protein complex involved in
various diseases. But a number of factors can contribute to
the challenge of identifying small molecules that inhibit such
interactions. These include the general lack of small-molecule
starting points for drug design, the typical flatness of the inter-
face, and the difficulty of distinguishing real from false bind-
ing, and the size and character of typical small-molecule
libraries (Arkin and Wells, 2004). However, much of these
problems have been solved through advancement of molecularbiology and computational modeling techniques (Jin et al.,
2013; Cheng et al., 2007; Huang and Jacobson, 2010).
2. Protein–protein interfaces: structure, composition and forces
Protein–protein interaction sites are formed by proteins with
good shape and electrostatic complementarity (Janin, 1995;
Jones and Thornton, 1996; Janin and Chothia, 1990). The
standard size for the protein interfaces are 1200–2000 A2
(Horton and Lewis, 1992). Small protein interfaces of size
1150–1200 A2 are usually unstable and short-lived (Conte
et al., 1999). Large protein interfaces are found in proteases,
G-proteins and other proteins of the signal transduction path-
ways (Janin and Chothia, 1990; Horton and Lewis, 1992).
Protein–protein interfaces are mostly hydrophobic and con-
sist of buried non polar surface area (Young et al., 1994). Thus
hydrophobicity is the leading force in protein–protein interac-
tions. The protein–protein complex is stabilized by a large gain
in free energy change through increase in entropy, van der
waals interactions and desolvation energy (Fernandez and
Scheraga, 2003; Dill, 1990). Besides hydrophobic interactions,
electrostatic forces also promote complex formation, which in
turn defines the lifetime of protein complexes (Nicolini, 1999).
It has been found that the average number of hydrogen bonds
is proportional to the subunit area surfaces: one bond per
100–200 A (Jones and Thornton, 1997a,b). Other hydrogen
bonds are formed between protein contacts and surrounding
water molecules (Laskowski et al., 1996; Vaughan et al., 1999).
It has been found that there is a highly uneven distribution
of energetic contribution of individual protein residues across
each subunit surface such that only a fraction of key residues
contribute to the binding free energy of protein–protein com-
plexes known as hot spots (Janin and Chothia, 1990; Conte
et al., 1999). Hot spots have been defined as those sites where
alanine mutations cause a significant increase in the binding
free energy of at least 2.0 kcal/mol (Thorn and Bogan, 2001).
In a protein–protein interface only a subset of the buried
amino acids contribute most of the binding affinity which is
determined by a change of free energy upon mutation of the
residue to an alanine. These hot spots are not only helpful
for the study of a single protein–protein dimer but also in
the determination of probable binding sites for other binding
partners (Thornton, 2001).
Figure 1 (A) The electrostatic potential surface of the protein complex formed between human growth hormone and growth hormone
receptor [PDB ID: 1A22]. (B) Close up view of the two hot spot residues of the growth hormone receptor TRP 104 and TRP 169 depicted
in ball and stick models (green) UCSF Chimera v 1.6.1 software was used to produce this picture.
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The most important ones are tryptophan (21%), arginine
(13.3%), and tyrosine (12.3%) (Moreira et al., 2007). In a pro-
tein complex formed between the human growth hormone and
human growth hormone binding protein it is well illustrated
that out of 29 interfacial residues only four residues with
DG> 4.5 kcal/mol were found to be hot spots and two of
them were tryptophan (Moreira et al., 2007). Fig. 1A shows
the electrostatic potential surface of the protein complex
formed between human growth hormone and growth hormone
receptor and Fig. 1B shows two hot spot residues TRP 104 and
TRP 169 of the growth hormone receptor. The high propensity
of tryptophan as hot spots is due to its large size and aromatic
nature (Samanta et al., 2000). Further, the common residues
which are disfavoured as hot spots are leucine, serine, thre-
onine and valine because these residues determine distinctive
protein structures (Bogan and Thorn, 1998).
Through detailed analysis of X-ray structures of 23 pro-
tein–protein complexes and binding free energy change upon
alanine mutation, Bogan and Thorn suggested that the hot
spot residues are surrounded by residues which are not impor-
tant in binding but in shielding these hot spots from the solvent
(Bogan and Thorn, 1998). This idea came to be known as O-
ring theory as there structures that resemble the alphabet O.
This theory is well supported by three observations. First,
the hot spots in X-ray protein complex structures often have
zero or low solvent accessible surface area. Second, many resi-
dues which are protected from solvent do not make significant
contributions to the binding free energy Third, there are no
residues with high solvent accessibility that make a large con-
tribution to DG binding (Bogan and Thorn, 1998). Thus, inac-
cessibility to the solvent is defined to be one condition as a
binding hot spot (Bogan and Thorn, 1998; Delano, 2002).
The residues surrounding hot spots should be able to establish
both hydrogen bonding and hydrophobic interactions in order
to occlude the solvent. Such residues can be tryptophan, tyro-
sine or asparagine. Although, O-ring theory is the most accept-
able hypothesis it does not have conclusive evidence. For
example, the assumption that non hot spot residues do not
contribute to binding is valid only if water or nearby sidechains are not able to effectively substitute the eliminated
atoms (Janin, 1999).
3. Thermodynamics and kinetics of protein–protein interactions
The formation of a protein–protein complex may be written as
Aþ B$kon
koff
AB ð1Þ
where kon is the second-order rate constant for the association
reaction and koff is the first order rate constant for the dissoci-
ation reaction. Their ratio is the equilibrium constant for asso-
ciation (Ka) or for dissociation (Kd) according to the law of
mass action and can be expressed as
½A½B
½AB ¼ Kd ¼
1
Ka
¼ koff
kon
ð2Þ
The main thermodynamic parameters characterizing protein–
protein complex- Gibb’s free energy change (DG), entropy
change (DS) and enthalpy change (DH) are inter- related by
the following equations.
DG ¼ RT lnKd ð3Þ
DG ¼ DH TDS ð4Þ
where DG is the standard free energy change, R is a gas con-
stant and T is absolute temperature and Kd is the equilibrium
constant. So using Eq. (3) it is possible to estimate free energy
change by determining Kd value. The Kd values for typical pro-
tein complexes lie in the range 104–1014 M which corre-
sponds to a free energy change of 6–19 kcal/mol (kleanthous,
2000).Change of enthalpy DH depends on hydrogen bond for-
mation, electrostatics and van der waals forces of interactions
whereas change of entropy DS depends on the degrees of free-
dom of the system. When proteins form tight complexes the
measurement of Kd value from kinetic methods is preferred
over the equilibrium method. As a rule a point mutation in
the protein interface reduces the affinity of the complex such
that a mutation causes an increase in the dissociation rate
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stant (kon) (Kleanthous, 2000; Schreiber et al., 1997).
4. Bioinformatics and proteomic methods for investigating
protein–protein interaction
4.1. In silico prediction of protein–protein interactions
Some in silico methods in predicting protein–protein interac-
tions are annotation by sequence similarity, phylogenetic pro-
filing, metabolic pathway mapping, gene neighbor and domain
fusion analyses. Annotation by sequence similarity involves
finding homologous counterparts of the query protein in anno-
tated databases using pairwise local sequence alignment
(Bergga˚rd et al., 2007). This method predicts the functional
partners of the query protein of the given organism with pro-
teins involved in complex formation in other organisms. The
basis of phylogenetic profiling of proteins involved in complex
formation is that such proteins must be present or absent
together in different organisms. A phylogenetic profile gives
the occurrence of a certain protein in a set of organisms. If
two or more proteins share a similar phylogenetic profile it is
possible that these proteins are functionally linked
(Eisenberg et al., 2000). Another method of predicting func-
tional linkages between two proteins is gene neighborhood
method. If two proteins are found in the neighborhood across
different organisms in the genome then it is highly probable
that these proteins could be functionally linked. This method
could correctly identify functional links among eight enzymes
of arginine biosynthesis of Mycobacterium tuberculosis
(Eisenberg et al., 2000). Fused domain analysis method is
based on the principle that two proteins are said to function-
ally linked in an organism if they correspond to different
domains of a single protein in other organisms. A typical
example of fused domain protein is P450BM-3. It consists of
two domains P450 102 and NADPH-cytochrome P450 reduc-
tase domains, whereas these are usually two separate proteinsTable 1 List of some freely accessed protein–protein interaction da
Database Type of information
DIP (Database of Interacting
Proteins)
Interactions (direct binding) betw
proteins
IntAct Interactions (direct binding) betw
proteins
BIND (Biomolecular Interaction
Network Database)
Interactions (binding) between
biomolecules
MINT (Molecular INTeraction
database)
Interactions (both direct and ind
relationships) between proteins
BRITE (Biomolecular Relations in
Information Transmission and
Expression)
Generalized interactions between
proteins (including direct binding
[part of KEGG]
InterDom Integrative database of putative
protein domain interactions
BID (Binding Interface Database) Detailed data on protein interfac
ASEdd (Alanine Scanning Energetics
database)
Energetics of side–chain interact
of heterodimeric interfaces, from
alanine scanning mutagenesis
KDBI (kinetic Data of Biomolecular
Interactions)
Kinetic parameters of protein–
protein and other interactions
PDB (Protein Data Bank) Atomic structures of proteins,
including those of protein complwhich interact with each other (Ruettinger et al., 1989). Meta-
bolic profiling also helps in predicting protein–protein interac-
tions. It has been found that proteins involved in coupled
enzymatic reaction form a temporary complex (Gomez and
Rzetsky, 2002).
4.2. Protein–protein interaction databases
Several databases contain experimental information on pro-
tein–protein interactions. Because of variability in different
experimental techniques the experimental information also
varies on a wide range. The data submitted in the databases
come from various sources such as high-throughput, data min-
ing, small scale experiments etc. Some of the free access pro-
tein–protein interaction databases are listed in Table 1.
4.3. Proteomics methods for the detection and analysis of
protein–protein interactions
4.3.1. Two hybrid system
The two hybrid system is a genetic method that measures pro-
tein–protein interactions on the basis of transcriptional activ-
ity. It relies on site specific transcriptional activators that
consist of two domains- DNA binding (DB) domain and Tran-
scriptional Activation (TA) domain (Hope and Struhl, 1986).
The DB domain helps the activator to bind to the promoter
of specific genes and the TA domain helps to recruit the tran-
scriptional protein machinery to begin the transcription pro-
cess. The two hybrid system method is based on the
principle that for a gene expression the DB and TA domains
of the activator have to be covalently linked or can be brought
near to each other by protein–protein interaction. Fig. 2 shows
the interaction between hypothetical proteins X and Y which
bring the DNA binding domain (DBD) and Transcriptional
Activation domain (TAD) in close proximity to each other
and results in reporter gene expression. Any two proteins X
and Y whose interaction is to be studied are tagged with thetabases.
URL References
een http://dip.doe-mbi.ucla.edu Salwinski et al. (2004)
een http://www.ebi.ac.uk/intact Hermjakob et al. (2004)
http://www.bind.ca/ Bader et al. (2003)
irect http://mint.bio.uniroma2.it/mint/ Zanzoni et al. (2002)
)
http://www.genome.jp/brite/ Kanehisa et al. (2004)
http://interdom.lit.org.sg Ng et al. (2003)
es http://tsailab.org/BID/ Fischer et al. (2003)
ions http://www.asedb.org Thorn and Bogan (2001)
kdbi/kdbi.asp Ji et al. (2003)
exes
http://www.rcsb.org/pdb/ Berman et al. (2000)
Figure 2 The two hybrid system: the interaction between proteins X and Y bring the DNA binding domain (DBD) and Transcriptional
Activation domain (TAD) in close proximity to each other and results in reporter gene expression.
Figure 3 (A–D) Sequential steps involved in co-immunoprecipitation for the detection of protein–protein complexes in a protein
mixture.
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taining reporter genes. If the two proteins interact with each
other it brings DB and TA domains of the activator in close
proximity and this functionally active transcriptional activator
in turn switches on the reporter gene expression. Various ver-
sions of the two hybrid system are available in which the DB
domains can be derived from yeast Gal4 protein (Chien
et al., 1991) or Escherichia coli Lex A protein (Vojtek et al.,
1993) and the TA domains can be derived from Gal4 protein
(Chien et al., 1991) or herpes simplex virus VP16 protein
(Dalton and Treisman, 1992). The reporter genes include
E. coli lacZ gene (Fields and Song, 1989) and selectable yeast
genes such HIS3 (Durfee et al., 1993) and LEU2 (Zervos
et al., 1993).
4.3.2. Co-immunoprecipitation
Co immunoprecipitation (Co-IP) is a commonly used tech-
nique for the determination of protein–protein interaction
(Bergga˚rd et al., 2007). In this method, protein–protein com-
plexes from a cell lysate or protein mixture are captured using
a specific antibody. Then, the antibody is immobilized using
protein A or protein G covalently attached to Sepharose
beads. After washing of the beads, the antibody and protein–
protein complexes are eluted (e.g., by boiling). The bound pro-
teins can then be identified by MS or by immunoblotting.
Fig. 3 shows sequential steps (A–D) involved in co-
immunoprecipitation for the detection of protein–protein com-
plexes in a protein mixture. There are two ways of performing
Co-IP- (i) Co-IP from cell-lines or tissues expressing their
endogenous proteins. The advantage of this approach is that
endogenous protein complexes can also be studied. The disad-
vantage is that highly specific antibodies are required. (ii) Thesecond approach is by using cells transfected with a plasmid
encoding a tagged bait protein (Masters, 2004). The advantage
of this approach is that there are minimum chances of cross
reactivity with other proteins as it is expected that the antibody
directed against the tag is highly specific.
4.3.3. Confocal microscopy
The basis of the confocal microscopy method is that if two or
more proteins are co-localized in a cell then it is highly proba-
ble that they also interact with each other in vivo (Miyashita,
2004). In this method cells are transfected using plasmids that
encode first protein fused to a tag and second protein fused to
a different tag. Next, the sample is incubated with secondary
antibodies labeled with different fluorophores (e.g., Cy2 and
Cy3). Because the two fluorophores will display different emis-
sion maxima, the intracellular localization of the proteins can
be monitored (Bergga˚rd et al., 2007). If the two proteins are
colocalized, the fluorescent probes will also be colocalized.
4.3.4. Surface plasmon resonance (SPR)
SPR is another widely used technique for the study of protein–
protein interactions (Szabo et al., 1995; Huber and Mueller,
2006). The two important advantages of this method are firstly
very little sample is required (mg) and secondly there is no need
for labeling samples. This method provides information not
only on affinities but also on the rates of association and dis-
sociation between protein–protein complexes in regulatory
pathways. This method can be applied for all kinds of proteins,
because it relies on the phenomenon of SPR attributed to thin
metal films (eg., gold or silver) and the signal recorded (the
angle of minimum reflected light) depends on the refractive
index close to the surface (Bergga˚rd et al., 2007).
384 A.B. Gurung et al.4.3.5. Isothermal titration calorimetry (ITC)
ITC has been used extensively in studying protein–ligand and
protein–protein interactions (Freire et al., 1990; Doyle, 1997;
Jelessarov and Bosshard, 1999). Protein–protein interactionFigure 4 Three different classes of PPI modulators: (A) binding pose
Menin [Protein Data Bank (PDB) code: 4GQ4]. (B) Binding pose an
BRaf [PDB code: 3OMV]. (C) Binding pose and molecular interaction
complex [PDB code: 1R8Q] the binding site of the ligand is indicated b
software v1.1.brings changes in the thermodynamic parameters such as
DG, DH and DS, which can be measured by the highly sensitive
calorimetry technique. Compared to SPR which needs the pro-
tein to be bound to the surface and which ultimately interferesand molecular interaction of orthosteric inhibitor MI-2-2 bound to
d molecular interaction of allosteric Inhibitor PLX4032 bound to
of interfacial binding inhibitor BFA bound to ARF1–Sec7 domain
y orange rectangular box. The pictures were taken using PYMOL
New approach to rational drug design 385with the binding or prolongs the duration of experiment, ITC
is much simpler and doesn’t need the protein to be adhered to
the surface (Velazquez-Campoy et al., 2004). Compared to the
other techniques which singly measure the binding affinity,
ITC measures both enthalpy as well as entropic components
of binding affinity (Velazquez-Campoy et al., 2004).
5. Protein–protein interaction as drug targets
Druggability is defined as modulating the function of a target
protein by small-molecules with high affinity (Hopkins and
Groom, 2002). Most of the proteins involved in disease path-
ways exert their functions through interactions with other pro-
teins, and they lack obvious druggable pockets for small
molecules. Although protein–protein interactions (PPIs) are
important in many cellular functions and disease pathways,
targeting protein–protein interaction with small molecule is a
challenging task. The main reasons are that protein–protein
interface hot spots are unevenly distributed across the protein
surfaces and secondly the shape of protein–protein recognition
sites which are mostly flat unlike protein–ligand recognition
sites which have deeper cleft (Jin et al., 2013). The druggability
issue with protein–protein contacts has greatly been solved
with the growing computational modeling methods (Cheng
et al., 2007; Huang and Jacobson, 2010), X-ray crystallogra-
phy techniques and the advancement of fragment based drug
discovery(Huang and Jacobson, 2010; Braisted et al., 2003).
Some examples of PPI modulators include molecules that
inhibit the recognition of IL-2 by its receptor IL2Ra
(Braisted et al., 2003), the binding of tumor suppressor p53
to its E3 ligase MDM2 (Vassilev, 2004) and the binding of
Bcl2/Bcl-XL to the proapoptotic molecule BAK (Oltersdorf
et al., 2005). There are three different mechanisms by which
small molecules inhibit PPI- orthosteric inhibition, allosteric
regulation, and interfacial binding/stabilization. The first
mechanism, orthosteric inhibition, involves direct competition
against the interacting partners. The orthosteric inhibitors
bind to the target proteins at sites that overlap with the areas
used for interacting with the partner proteins, thus directly
inhibiting the formation of macromolecular complexes. Some
examples in this category include the inhibitors against theFigure 5 Structures of hot spot-based design of spirooxindole corMenin-MLL complex, the bromodomain-acetylated histone
complex, the Ras-SOS1 complex, and the xIAP-caspase inter-
action (Flygare et al., 2012). Fig. 4A shows orthosteric inhibi-
tor MI-2-2 bound to Menin. The second mechanism, allosteric
regulation involves binding of small molecules to target pro-
teins at sites distinct from the macromolecular interface. Bind-
ing of the ligand induces changes in conformation and
prevents the macromolecular interaction in an allosteric man-
ner. Some examples of allosteric inhibitors include the PLX
series of BRaf inhibitors that block BRaf-CRaf heterodimer-
ization and activation (Hatzivassiliou et al., 2010). Fig. 4B
shows allosteric Inhibitor PLX4032 bound to BRaf. The third
category includes interfacial binders, whereby the ligand and
proteins form a ternary complex. An interfacial inhibitor binds
to a pocket at the macromolecular interface and locks the com-
plex into a nonfunctional conformation. A representative
example in this category is brefeldin A (BFA). Fig. 4C shows
interfacial binding inhibitor BFA bound to ARF1–Sec7
domain complex. BFA is a natural compound that traps
ADP-ribosylation factor (ARF) and Sec7-domain-containing
ARF exchange factors in a dead-end complex and inhibits
the nucleotide exchange reaction for ARF (Mossessova
et al., 2003).
There are several examples of hot spot based drug design.
This includes a series of spirooxindole containing inhibitors
such as MI-63 and MI-888 for murine double minute 2
(MDM2)/tumor suppressor p53 interactions can inhibit the
growth of cancers with wild type p53 (Guo et al., 2014).
Fig. 5A and B shows the chemical structure of spirooxindole
core containing MDM2/p53 PPI inhibitors MI-63 MI-888
respectively. The oxindole moiety of the spirooxindole core
was designed to mimic the binding mode of the side chain of
p53 TRP23 (Guo et al., 2014). The MI-63 and MI-888 inhibi-
tors were designed using hot spot based approach and exhibits
Ki value of 0.003 ± 0.0015 lM and 0.00044 ± 0.00022 lM
respectively (Ding et al., 2006; Zhao et al., 2013).
Another example of hot spot based PPI inhibitor design
include inhibitors for von Hippel–Lindau (VHL)/hypoxia-
inducible factor 1a (HIF1a) interactions (Buckley et al.,
2012). The formation of the VHL/HIF1 protein complex pro-
motes the ubiquitination and degradation of HIF1a by thee containing MDM2/p53 PPI inhibitors (A) MI-63 (B) MI-888.
Figure 6 Structure of hot spot-based design of hydroxyproline-
containing VHL/HIF1a PPI inhibitor.
Figure 7 Structure of hot spot-based design of b-catenin/T-cell
factor PPI inhibitor.
386 A.B. Gurung et al.proteasome and its abnormal activity has also been implicated
in chronic anemia (Ziello et al., 2007). It was found that 3-
Hydroxyl-L-proline (Hyp) 564 of HIF1a is an important hot
spot for interacting with VHL (Guo et al., 2014). This residue
was used as a starting point to design a new inhibitor which
exhibited an IC50 value of 117 ± 10 l M (Guo et al., 2014).
Fig. 6 shows the chemical structure of hydroxyproline-
containing VHL/HIF1 a PPI inhibitor.
Ji and coworkers used the fragment hopping approach for
the design of potent and selective PPI inhibitors (Ji et al.,
2008). Fragment hopping method is a new fragment based
approach of drug design that requires the extraction of key
binding elements based on the binding mode between the pro-
jecting hot spots and the concave hot spot pocket (Guo et al.,
2014). This approach was employed to design effective as well
as selective inhibitors for b-catenin/T-cell factor (Tcf) interac-
tions (Yu et al., 2013).The aberrant formation of b-catenin/Tcf
protein–protein complex is known to hyper activate Wnt tar-
get genes that eventually cause the initiation and progression
of many cancers and fibroses (Van de Wetering et al., 2002).
UU-T01 inhibitor was designed which mimics the binding
mode of side chain carboxylic acids of Tcf4 D16 and E17
and exhibit Ki values 3.14 ± 0.48 l M (Guo et al., 2014).
Fig. 7 shows the chemical structure of b-catenin/T-cell factor
PPI inhibitor UU-T01. This compound completely disrupts
b-catenin/Tcf interactions and is two orders of magnitude
more potent than known dipeptides (Guo et al., 2014).6. Conclusions
Protein–protein interaction is an essential process in the cell
but its aberrant activities such as alteration of downstream
target genes may lead to many disease conditions. Though
targeting protein–protein interactions with small molecules
theoretically seems feasible it is itself a challenging task. Some
of the bottlenecks are lack of a deeper cleft in the binding site,
difficulty in identification of hot spot residues, diversity in pro-
tein–protein interactions etc. But with the rapid advancement
in computational methods and molecular biology techniques,
it has been possible to design modulators which can either
destabilize protein–protein interaction or render the protein
complexes inactive by locking the complexes in a nonfunc-
tional state. Such approaches will have a great impact in
pharmaceutical sciences in developing modulators which can
restore the normal functions of protein–protein interactions
in disease pathways.
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